Your cart

×
Note: As of September 30th there will be order processing and shipment delays that may last until October 8, 2020 as we are transitioning to a new ERP system. Please email information@gyrosproteintech.com to discuss what accommodations we can provide during this time.

Designing peptides to meet the challenge of the next generation of druggable targets

Jul 30, 2020 9:49:00 AM

Targeting protein–protein interactions (PPIs) is a new challenge in expanding druggable space. Cyclic peptides show promise in targeting PPIs and to better understand their structure–activity relationships a research team at Tufts University, USA, has analyzed a series of designed, well-structured cyclic hexapeptides and use simulations and experimental techniques to understand their global structural ensembles. They discovered a previously unappreciated role for β-branched residues in stabilizing specific conformations of cyclic hexapeptides, and their approach shows promise in the prediction of structure–activity relationships for drug development. Their work was rewarded by being on the front cover of Biophysical Journal, Volume 116, Issue 3.

Read More

Topics: Peptide synthesis, Protein-Protein Interactions (PPIs), Tribute peptide synthesizer, Cyclic peptides

Peptide inhibitor of methylation casts new light on epigenetic-based cancer therapy

Jul 1, 2020 12:00:00 AM

The first peptide-derived epigenetic drug (Romidepsin) was approved in 2009 for the treatment of cutaneous T cell lymphomas (CTCL), and in 2011 for peripheral T cell lymphomas (PTCL) (2). Romidepsin also has potential in the treatment of other kinds of cancer, lung fibrosis, and Epstein-Barr infections. Currently, it is the only FDA-approved peptide medicine specifically designed to target epigenetic effects. Nesiritide, a peptide originally approved in 2001 for the symptomatic treatment of acute decompensated heart failure due to its vasodilating activity has since been repurposed due to its epigenetic effects. These peptides are not yet approved in the European Union by the EMA.

Read More

Topics: Prelude, Peptide synthesis, Protein-Protein Interactions (PPIs), Peptide synthesizer, Cyclic peptides